Yu Xia - Oct 21, 2025 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Role: Director
Signature: /s/ Adam Finerman, as Attorney-in-Fact for Yu Xia
Stock symbol: SMMT
Transactions as of: Oct 21, 2025
Transactions value $: $9,999,983
Form type: 4
Date filed: 10/23/2025, 09:06 PM
Previous filing: Jan 6, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Xia Yu	Director	C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI	/s/ Adam Finerman, as Attorney-in-Fact for Yu Xia	2025-10-23	0001963544

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SMMT	Common Stock	Purchase	$10M	+534K	+1.69%	$18.74	32.1M	Oct 21, 2025	Akeso, Inc.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.
F2	Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 25.96% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest.

Content

Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.

Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 25.96% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest.